rapifleX MALDI PharmaPulse
New standard for ultra-High-Throughput Screening Label-Free ‘Hit’ Identification
The rapifleX MALDI PharmaPulse (MPP) accelerates label-free hit finding in drug discovery: rapifleX MPP combines the unambiguousness of mass spectrometry with the required speed to comb through large compound libraries of millions of substances.
The use of mass spectrometry allows the measurement of unmodified substrates in primary screens to avoid false positives or false negatives, making confirmation screens redundant. The system is designed for fully automatic handling of 1536 sample plates to screen more than a million compounds in a week in support of drug discovery.
By combining the speed of Bruker’s patented Smartbeam™ 3D laser technology with the direct-detection capability of mass spectrometry, the rapifleX MALDI PharmaPulse (MPP) delivers unprecedented screening capability for High-Throughput Screening biochemical assays. It allows you to screen through large and diverse compound libraries at a pace of over a million compounds a week, epitomizing the perfect balance of automation and miniaturization.
For more information; click here.
